Pathway Genomics Introduces BRCA1/2 Genetic Test with One for One Program

Pathway Genomics said that it has launched BRCATrue, a next- generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer.

BRCATrue has a sensitivity of greater than 99.99 percent and the broadest coverage across BRCA1/2 in the industry, the Company noted in its release.

To enhance the accessibility of this genetic test, Pathway Genomics said that it has developed the BRCA One for One program - for every qualified BRCATrue test ordered, one test is donated to a person in need through patient advocacy organizations, up to $10 million of free testing.

"Pathway's mission is to ensure that people in need receive genetic testing regardless of their economic or insurance status," said Jim Plante, Pathway Genomics' founder and CEO. "Offering the industry's best BRCA genetic test and making it accessible to a wide range of people is a vital objective in this mission."

"One out of every eight women will be affected by breast cancer in her lifetime," said Ardy Arianpour, Pathway Genomics' chief strategy officer. "In the history of the medical community, no clinical laboratory has offered such an unprecedented program as BRCA One for One. By making our test more accessible, we aim to make a substantial impact in the prevention of breast cancer and help further raise awareness by partnering with global patient advocacy organizations."

More Information:

www.pathway.com/brcatrue

www.brcaoneforone.com

((Comments on this story may be sent to [email protected]))